Shots:
- Cue Biopharma has entered into an exclusive license agreement with Ascendant Health Sciences to develop, manufacture and commercialize Ascendant-221 for the treatment of allergic diseases
- As per the deal, Cue will obtain global rights (excl. Greater China) to develop & commercialize Ascendant-221 in exchange for $15M upfront license fee, ~$676.5M in development, regulatory & commercial milestones, and tiered royalties on future sales
- Ascendant-221, an anti-IgE mAb, is being evaluated in a P-II dose-ranging study against PBO for chronic spontaneous urticaria in China, with results expected in H2’26, after which Cue plans to initiate a global P-IIb trial in food allergy
Ref: Globenewswire | Image: Cue Biopharma | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
